[VIEW] agent=Risk & Compliance Officer | scenario_id=120 | rounds=20

--- Round 0 ---
[R0.1] Risk & Compliance Officer (speak, public): To evaluate the potential launch of the pharmacist-led telehealth anticoagulation management service, we need to focus on a few critical areas. First, can we confirm the clinical effectiveness of the proposed model? Secondly, how do we ensure operational capacity aligns with our current resources? Lastly, I would like to understand the financial sustainability and how the payer reimbursement structures will support this initiative. Let's also keep in mind any regulatory constraints that may impact our implementation. I believe these points will help us identify any risks involved in the launch.
[R0.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): Thank you for bringing up those critical areas. I can confirm that our pilot program demonstrated significant clinical effectiveness, with a TTR improvement from 52% to 68% across 180 patients. For operational capacity, we estimate being able to enroll about 640 eligible patients per quarter, with a current pilot enrollment rate of 28%. Regarding financial sustainability, we will need to explore the payer reimbursement structures to ensure they can support our staffing model of 1.8 pharmacist FTEs and 0.6 RN FTEs per 500 active patients. Additionally, we should address any regulatory constraints that could impact our implementation. Let's discuss these points further to ensure a comprehensive evaluation.
[R0.3] Payer Contracting & Finance Manager (speak, public): I appreciate the insights shared regarding clinical effectiveness and operational capacity. To ensure financial sustainability, we need to align our reimbursement structures with the expected demand. Based on our model, we're looking at a per-episode reimbursement of $62, with a projected volume of 9,600 episodes annually. Could we delve into how this aligns with your staffing model and if there are any potential adjustments needed for the anticipated patient volume? Additionally, have we identified any specific regulatory risks that could impede our operational readiness?

--- Round 1 ---
[R1.1] Risk & Compliance Officer (speak, public): Thank you for the information regarding clinical effectiveness and financial sustainability. The projected volume and reimbursement model seem promising, but we must ensure that the alignment with our staffing model is realistic given our current operational capacity. Regarding regulatory risks, we need to carefully assess any compliance requirements that could affect our implementation timeline. I would suggest we conduct a thorough review of any applicable regulations, particularly focusing on telepharmacy compliance and patient safety protocols. This will help us mitigate potential risks before we proceed further. Can we set a timeline for this review?
[R1.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): I agree that setting a timeline for the regulatory review is crucial. Given the complexities of telepharmacy compliance, I suggest we aim to complete this review within the next month. This will allow us to identify any potential barriers early and ensure we can align our operational capacity accordingly. Let's collaborate on establishing a clear timeline and responsibilities for this review process.
[R1.3] Payer Contracting & Finance Manager (speak, public): I agree with the proposed timeline for the regulatory review; completing it within a month is achievable and will provide us with the necessary insights to proceed confidently. Additionally, we should analyze the current staffing model to ensure it aligns with our reimbursement structure of $62 per episode. With a projected volume of 9,600 episodes annually, we should verify that our staffing levels of 1.8 pharmacist FTEs and 0.6 RN FTEs can accommodate this demand. Let's ensure we have a clear plan moving forward that addresses both our clinical and operational needs while adhering to regulatory requirements.

--- Round 2 ---
[R2.1] Risk & Compliance Officer (speak, public): I appreciate everyone's input on the clinical effectiveness, operational capacity, and financial sustainability of the proposed telehealth anticoagulation management service. To ensure we are all aligned, I propose we finalize our timeline for the regulatory review by the end of this week, so we can proceed without delays. I also suggest we set up a follow-up meeting to discuss the findings of this review and any adjustments needed for our staffing model based on the reimbursement structure. Does that sound agreeable to everyone?
[R2.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): I fully support the proposal to finalize our timeline for the regulatory review by the end of this week. It’s crucial we have a clear understanding moving forward. Additionally, I agree to set up a follow-up meeting to discuss our findings and make any necessary adjustments to our staffing model based on the reimbursement structure. Let’s ensure we’re all prepared with our respective areas of focus for that discussion.
[R2.3] Payer Contracting & Finance Manager (speak, public): I agree with finalizing the timeline for the regulatory review by the end of this week. It’s essential that we stay on track to ensure smooth progress. Once we have the findings from the review, we can make any necessary adjustments to our staffing model based on the reimbursement structure. I look forward to our follow-up meeting to discuss this further and will prepare my insights accordingly.

--- Round 3 ---
[R3.1] Risk & Compliance Officer (leave, public): 
[R3.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R3.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 4 ---
[R4.1] Risk & Compliance Officer (leave, public): 
[R4.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R4.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 5 ---
[R5.1] Risk & Compliance Officer (leave, public): 
[R5.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R5.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 6 ---
[R6.1] Risk & Compliance Officer (leave, public): 
[R6.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R6.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 7 ---
[R7.1] Risk & Compliance Officer (leave, public): 
[R7.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R7.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 8 ---
[R8.1] Risk & Compliance Officer (leave, public): 
[R8.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R8.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 9 ---
[R9.1] Risk & Compliance Officer (leave, public): 
[R9.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R9.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 10 ---
[R10.1] Risk & Compliance Officer (leave, public): 
[R10.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R10.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 11 ---
[R11.1] Risk & Compliance Officer (leave, public): 
[R11.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R11.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 12 ---
[R12.1] Risk & Compliance Officer (leave, public): 
[R12.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R12.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 13 ---
[R13.1] Risk & Compliance Officer (leave, public): 
[R13.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R13.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 14 ---
[R14.1] Risk & Compliance Officer (leave, public): 
[R14.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R14.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 15 ---
[R15.1] Risk & Compliance Officer (leave, public): 
[R15.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R15.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 16 ---
[R16.1] Risk & Compliance Officer (leave, public): 
[R16.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R16.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 17 ---
[R17.1] Risk & Compliance Officer (leave, public): 
[R17.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R17.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 18 ---
[R18.1] Risk & Compliance Officer (leave, public): 
[R18.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R18.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 19 ---
[R19.1] Risk & Compliance Officer (leave, public): 
[R19.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R19.3] Payer Contracting & Finance Manager (leave, public): 

